Los Angeles, California 90033

  • Head and Neck Cancer


The objective of this study is to assess safety and efficacy of CAB-ROR2-ADC in solid tumors

Study summary:

This is a multi-center, open-label, Phase 1/2 study designed to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of BA3021, a conditionally active biologic (CAB) ROR2-targeted antibody drug conjugate (CAB-ROR2-ADC) BA3021 in patients with advanced solid tumors. This study will consist of a dose escalation phase and a dose expansion phase with BA3021 in Phase 1. Phase 2 will study BA3021 alone or in combination with a PD-1 inhibitor.


Inclusion Criteria: - Patients must have histologically or cytologically confirmed locally advanced unresectable or metastatic solid tumor and have failed all available standard of care (SoC) therapy and for whom no curative therapy is available or who are not eligible, intolerant to or refuse standard therapy. - Patients must have measurable disease. - For the dose expansion phase: Patients with locally advanced unresectable or metastatic, non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC) and soft tissue sarcoma (STS) - Age ≥ 18 years. - Adequate renal function - Adequate liver function - Adequate hematological function - Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. - Life expectancy of at least three months. Exclusion Criteria: - Patients must not have clinically significant cardiac disease. - Patients must not have known non-controlled CNS metastasis. - Patients must not have a history of ≥ Grade 3 allergic reactions to mAb therapy as wellas known or suspected allergy or intolerance to any agent given during this study. - Patients must not have had major surgery within 4 weeks before first BA3021 administration. - Patients must not have had prior therapy with a conjugated or unconjugated auristatin derivative/vinca-binding site targeting payload. - Patients must not have known human immunodeficiency virus (HIV) infection, active hepatitis B and/or hepatitis C. - Patients must not be women who are pregnant or breast feeding.



Primary Contact:

Study Director
Philippe Martin
BioAtla, Inc.

Hazel Buncab
Phone: 858-263-1598 ext. 8582631598
Email: hbuncab@bioatla.com

Backup Contact:

Email: jlee@bioatla.com
Ji Hwan Lee
Phone: 858-286-7702

Location Contact:

Los Angeles, California 90033
United States

Jessica Levano
Email: Jessica.Levano@med.usc.edu

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: March 24, 2023

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.